Blockchain Registration Transaction Record

Quantum BioPharma Pursues New Path for Multiple Sclerosis Treatments

Quantum BioPharma (NASDAQ: QNTM) advances Lucid-MS, a novel multiple sclerosis treatment targeting demyelination. With MS prevalence rising, could this be a breakthrough?

This news matters because multiple sclerosis affects nearly three million people globally, yet no current therapy reverses the neurodegeneration that causes long-term disability. Quantum BioPharma’s Lucid-MS, which targets an enzyme involved in demyelination, could offer a first-in-class approach for progressive forms of MS. If successful, it would fill a critical gap in treatment options, potentially slowing or stopping disease progression and improving quality of life for patients. For investors, it represents a high-reward opportunity in a space with substantial unmet need and growing prevalence.